Skip to main content

Search

Reset all filters
393 Result(s)
Sort by

Weight Loss from Cancer Treatment

Weight Loss from Cancer Treatment

Discover advice on how to put weight back on following cancer treatment from Taking Cancer On Through Flavour
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Taking cancer on together

Taking cancer on together

Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.
Our Partners Bioharmony

Our Partners Bioharmony

Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Taking Cancer on at Diagnosis

Taking Cancer on at Diagnosis

We spoke to Markus, Brigitte and Dr Hochmair who shared their advice for people starting their own cancer journeys.
Protein Degraders in Cancer

Protein Degraders in Cancer

Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Dedifferentiated liposarcoma (DDLPS)

Dedifferentiated liposarcoma (DDLPS)

An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Win Fight Against Cancer

Win Fight Against Cancer

At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Veganism

Veganism

Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
clinical-collaboration-with-Amgen

clinical-collaboration-with-Amgen

Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor